ペプチド・オリゴヌクレオチドCDMOの世界市場成長(現状と展望) 2023-2029Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2023-2029 弊社(LP Info Research)の最新調査によると、世界のペプチド・オリゴヌクレオチドCDMO市場規模は2022年に1億5,652万米ドルとなった。川下市場での需要拡大とCOVID-19やロシア・ウクライナ戦争の影響からの回復... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー弊社(LP Info Research)の最新調査によると、世界のペプチド・オリゴヌクレオチドCDMO市場規模は2022年に1億5,652万米ドルとなった。川下市場での需要拡大とCOVID-19やロシア・ウクライナ戦争の影響からの回復により、ペプチド・オリゴヌクレオチドCDMOはレビュー期間中のCAGR10.4%で2029年までに3億1234万米ドルの再調整規模になると予測されている。この調査レポートは、世界のペプチドおよびオリゴヌクレオチドCDMO市場の成長の可能性を明らかにしています。COVID-19やロシア・ウクライナ戦争の影響からの回復に伴い、ペプチド・オリゴヌクレオチドCDMOは今後の市場でも安定した成長が見込まれる。しかし、ペプチド・オリゴヌクレオチドCDMOの普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場関係者は、ペプチド・オリゴヌクレオチドCDMO市場がもたらす莫大な機会を活用するために、研究開発に投資し、戦略的パートナーシップを築き、進化する消費者の嗜好に合わせた製品を提供する必要がある。 主な特徴 ペプチド・オリゴヌクレオチドCDMO市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。 市場規模と成長:この調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(例:ペプチドCDMO、オリゴヌクレオチドCDMO)、地域別内訳などが含まれます。 市場促進要因と課題:ペプチド・オリゴヌクレオチドCDMO市場の成長を促進する要因(政府規制、環境問題、技術進歩、消費者嗜好の変化など)を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も浮き彫りにすることができる。 競合情勢:この調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO市場における競争環境の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。 技術開発:調査レポートは、ペプチドおよびオリゴヌクレオチドCDMO産業における最新の技術開発を掘り下げることができます。これには、ペプチド・オリゴヌクレオチドCDMO技術の進歩、ペプチド・オリゴヌクレオチドCDMOの新規参入企業、ペプチド・オリゴヌクレオチドCDMOの新規投資、ペプチド・オリゴヌクレオチドCDMOの将来を形作るその他の技術革新が含まれます。 川下の事業者の好み:このレポートは、ペプチド・オリゴヌクレオチドCDMO市場における顧客の購買行動と採用動向を明らかにします。顧客の購買決定やペプチド・オリゴヌクレオチドCDMO製品の嗜好に影響を与える要因も含まれています。 政府の政策とインセンティブこの調査レポートは、政府の政策とインセンティブがペプチドおよびオリゴヌクレオチドCDMO市場に与える影響を分析しています。これには、ペプチドおよびオリゴヌクレオチドCDMO市場の促進を目的とした規制枠組み、補助金、税制優遇措置、その他の措置の評価が含まれる。また、市場成長促進におけるこれらの政策の有効性も評価する。 環境影響と持続可能性調査レポートは、ペプチド・オリゴヌクレオチドCDMO市場の環境影響と持続可能性の側面を評価します。 市場予測と将来展望:調査レポートでは、実施した分析に基づいて、ペプチドおよびオリゴヌクレオチドCDMO産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。 提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられている。市場関係者が新たなトレンドを活用し、課題を克服し、ペプチド・オリゴヌクレオチドCDMO市場の成長と発展に貢献するための潜在的な機会を強調しています。 市場のセグメンテーション ペプチド・オリゴヌクレオチドCDMO市場は、タイプ別と用途別に分割される。2018年から2029年までの期間について、セグメント間の成長は、タイプ別、アプリケーション別の消費額の正確な計算と予測を提供します。 タイプ別セグメント ペプチドCDMO オリゴヌクレオチドCDMO 用途別セグメント 製薬・バイオテクノロジー企業 研究機関 その他 本レポートではまた、市場を地域別に分けています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ロンザ・グループ サーモフィッシャーサイエンティフィック メルク KGaA キャタレント ジェンスクリプト・バイオテック・コーポレーション ポリペプチドグループ バケムホールディングAG 無錫アプテック株式会社 味の素株式会社 レントシュラーバイオファーマSE コーデンファーマ ゼンケミカルズAG アルマックグループ ロンザカスタムマニュファクチャリング クリエイティブペプチド スイスカスタマイズ合成 シンゲン ユーロジェンテック 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029 2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Peptide and Oligonucleotide CDMO Segment by Type 2.2.1 Peptide CDMO 2.2.2 Oligonucleotide CDMO 2.3 Peptide and Oligonucleotide CDMO Market Size by Type 2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023) 2.4 Peptide and Oligonucleotide CDMO Segment by Application 2.4.1 Pharmaceutical and Biotechnology Companies 2.4.2 Research Institutes 2.4.3 Others 2.5 Peptide and Oligonucleotide CDMO Market Size by Application 2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023) 3 Peptide and Oligonucleotide CDMO Market Size by Player 3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players 3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) 3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023) 3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Peptide and Oligonucleotide CDMO by Regions 4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023) 4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 5 Americas 5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) 5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) 6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023) 7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023) 8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Peptide and Oligonucleotide CDMO Market Forecast 10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029) 10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029) 10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast 10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast 10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast 10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast 10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029) 10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast 10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast 10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast 10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast 10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029) 10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast 10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast 10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast 10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast 10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast 10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast 10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029) 10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast 10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast 10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast 10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast 10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast 10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029) 10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast 10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast 10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast 10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast 10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast 10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029) 10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Lonza Group Ltd. 11.1.1 Lonza Group Ltd. Company Information 11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered 11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Lonza Group Ltd. Main Business Overview 11.1.5 Lonza Group Ltd. Latest Developments 11.2 Thermo Fisher Scientific Inc. 11.2.1 Thermo Fisher Scientific Inc. Company Information 11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered 11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Thermo Fisher Scientific Inc. Main Business Overview 11.2.5 Thermo Fisher Scientific Inc. Latest Developments 11.3 Merck KGaA 11.3.1 Merck KGaA Company Information 11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered 11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Merck KGaA Main Business Overview 11.3.5 Merck KGaA Latest Developments 11.4 Catalent, Inc. 11.4.1 Catalent, Inc. Company Information 11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered 11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Catalent, Inc. Main Business Overview 11.4.5 Catalent, Inc. Latest Developments 11.5 Genscript Biotech Corporation 11.5.1 Genscript Biotech Corporation Company Information 11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered 11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Genscript Biotech Corporation Main Business Overview 11.5.5 Genscript Biotech Corporation Latest Developments 11.6 Polypeptide Group 11.6.1 Polypeptide Group Company Information 11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered 11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Polypeptide Group Main Business Overview 11.6.5 Polypeptide Group Latest Developments 11.7 Bachem Holding AG 11.7.1 Bachem Holding AG Company Information 11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered 11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Bachem Holding AG Main Business Overview 11.7.5 Bachem Holding AG Latest Developments 11.8 Wuxi Apptec Co., Ltd. 11.8.1 Wuxi Apptec Co., Ltd. Company Information 11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered 11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview 11.8.5 Wuxi Apptec Co., Ltd. Latest Developments 11.9 Ajinomoto Co., Inc. 11.9.1 Ajinomoto Co., Inc. Company Information 11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered 11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Ajinomoto Co., Inc. Main Business Overview 11.9.5 Ajinomoto Co., Inc. Latest Developments 11.10 Rentschler Biopharma SE 11.10.1 Rentschler Biopharma SE Company Information 11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered 11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Rentschler Biopharma SE Main Business Overview 11.10.5 Rentschler Biopharma SE Latest Developments 11.11 Corden Pharma GmbH 11.11.1 Corden Pharma GmbH Company Information 11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered 11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Corden Pharma GmbH Main Business Overview 11.11.5 Corden Pharma GmbH Latest Developments 11.12 Senn Chemicals AG 11.12.1 Senn Chemicals AG Company Information 11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered 11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Senn Chemicals AG Main Business Overview 11.12.5 Senn Chemicals AG Latest Developments 11.13 Almac Group 11.13.1 Almac Group Company Information 11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered 11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Almac Group Main Business Overview 11.13.5 Almac Group Latest Developments 11.14 Lonza Custom Manufacturing 11.14.1 Lonza Custom Manufacturing Company Information 11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered 11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Lonza Custom Manufacturing Main Business Overview 11.14.5 Lonza Custom Manufacturing Latest Developments 11.15 Creative Peptides 11.15.1 Creative Peptides Company Information 11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered 11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Creative Peptides Main Business Overview 11.15.5 Creative Peptides Latest Developments 11.16 Swiss Customized Synthesis 11.16.1 Swiss Customized Synthesis Company Information 11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered 11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 Swiss Customized Synthesis Main Business Overview 11.16.5 Swiss Customized Synthesis Latest Developments 11.17 Syngene 11.17.1 Syngene Company Information 11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered 11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Syngene Main Business Overview 11.17.5 Syngene Latest Developments 11.18 Eurogentec 11.18.1 Eurogentec Company Information 11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered 11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.18.4 Eurogentec Main Business Overview 11.18.5 Eurogentec Latest Developments 12 Research Findings and Conclusion
SummaryAccording to our (LP Info Research) latest study, the global Peptide and Oligonucleotide CDMO market size was valued at US$ 1565.2 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Peptide and Oligonucleotide CDMO is forecast to a readjusted size of US$ 3123.4 million by 2029 with a CAGR of 10.4% during review period. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029 2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Peptide and Oligonucleotide CDMO Segment by Type 2.2.1 Peptide CDMO 2.2.2 Oligonucleotide CDMO 2.3 Peptide and Oligonucleotide CDMO Market Size by Type 2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023) 2.4 Peptide and Oligonucleotide CDMO Segment by Application 2.4.1 Pharmaceutical and Biotechnology Companies 2.4.2 Research Institutes 2.4.3 Others 2.5 Peptide and Oligonucleotide CDMO Market Size by Application 2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023) 3 Peptide and Oligonucleotide CDMO Market Size by Player 3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players 3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) 3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023) 3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Peptide and Oligonucleotide CDMO by Regions 4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023) 4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023) 5 Americas 5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) 5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) 6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023) 7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023) 8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) 8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Peptide and Oligonucleotide CDMO Market Forecast 10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029) 10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029) 10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast 10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast 10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast 10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast 10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029) 10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast 10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast 10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast 10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast 10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029) 10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast 10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast 10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast 10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast 10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast 10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast 10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029) 10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast 10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast 10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast 10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast 10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast 10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029) 10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast 10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast 10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast 10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast 10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast 10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029) 10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Lonza Group Ltd. 11.1.1 Lonza Group Ltd. Company Information 11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered 11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Lonza Group Ltd. Main Business Overview 11.1.5 Lonza Group Ltd. Latest Developments 11.2 Thermo Fisher Scientific Inc. 11.2.1 Thermo Fisher Scientific Inc. Company Information 11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered 11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Thermo Fisher Scientific Inc. Main Business Overview 11.2.5 Thermo Fisher Scientific Inc. Latest Developments 11.3 Merck KGaA 11.3.1 Merck KGaA Company Information 11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered 11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Merck KGaA Main Business Overview 11.3.5 Merck KGaA Latest Developments 11.4 Catalent, Inc. 11.4.1 Catalent, Inc. Company Information 11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered 11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Catalent, Inc. Main Business Overview 11.4.5 Catalent, Inc. Latest Developments 11.5 Genscript Biotech Corporation 11.5.1 Genscript Biotech Corporation Company Information 11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered 11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Genscript Biotech Corporation Main Business Overview 11.5.5 Genscript Biotech Corporation Latest Developments 11.6 Polypeptide Group 11.6.1 Polypeptide Group Company Information 11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered 11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Polypeptide Group Main Business Overview 11.6.5 Polypeptide Group Latest Developments 11.7 Bachem Holding AG 11.7.1 Bachem Holding AG Company Information 11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered 11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Bachem Holding AG Main Business Overview 11.7.5 Bachem Holding AG Latest Developments 11.8 Wuxi Apptec Co., Ltd. 11.8.1 Wuxi Apptec Co., Ltd. Company Information 11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered 11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview 11.8.5 Wuxi Apptec Co., Ltd. Latest Developments 11.9 Ajinomoto Co., Inc. 11.9.1 Ajinomoto Co., Inc. Company Information 11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered 11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Ajinomoto Co., Inc. Main Business Overview 11.9.5 Ajinomoto Co., Inc. Latest Developments 11.10 Rentschler Biopharma SE 11.10.1 Rentschler Biopharma SE Company Information 11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered 11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Rentschler Biopharma SE Main Business Overview 11.10.5 Rentschler Biopharma SE Latest Developments 11.11 Corden Pharma GmbH 11.11.1 Corden Pharma GmbH Company Information 11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered 11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Corden Pharma GmbH Main Business Overview 11.11.5 Corden Pharma GmbH Latest Developments 11.12 Senn Chemicals AG 11.12.1 Senn Chemicals AG Company Information 11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered 11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Senn Chemicals AG Main Business Overview 11.12.5 Senn Chemicals AG Latest Developments 11.13 Almac Group 11.13.1 Almac Group Company Information 11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered 11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Almac Group Main Business Overview 11.13.5 Almac Group Latest Developments 11.14 Lonza Custom Manufacturing 11.14.1 Lonza Custom Manufacturing Company Information 11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered 11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Lonza Custom Manufacturing Main Business Overview 11.14.5 Lonza Custom Manufacturing Latest Developments 11.15 Creative Peptides 11.15.1 Creative Peptides Company Information 11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered 11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Creative Peptides Main Business Overview 11.15.5 Creative Peptides Latest Developments 11.16 Swiss Customized Synthesis 11.16.1 Swiss Customized Synthesis Company Information 11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered 11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 Swiss Customized Synthesis Main Business Overview 11.16.5 Swiss Customized Synthesis Latest Developments 11.17 Syngene 11.17.1 Syngene Company Information 11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered 11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Syngene Main Business Overview 11.17.5 Syngene Latest Developments 11.18 Eurogentec 11.18.1 Eurogentec Company Information 11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered 11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) 11.18.4 Eurogentec Main Business Overview 11.18.5 Eurogentec Latest Developments 12 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他(治療を主目的としない薬物))の最新刊レポートLP Information 社の最新刊レポート本レポートと同じKEY WORD(peptide)の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/07 10:27 155.63 円 167.26 円 203.27 円 |